Synergistic airway gland mucus secretion in response to vasoactive intestinal peptide and carbachol is lost in cystic fibrosis

Jae Young Choi,1,2 Nam Soo Joo,1 Mauri E. Krouse,1 Jin V. Wu,1 Robert C. Robbins,3 Juan P. Ianowski,4 John W. Hanrahan,4 and Jeffrey J. Wine1

1Cystic Fibrosis Research Laboratory, Stanford University, Stanford, California, USA. 2Department of Otorhinolaryngology, Yonsei University, Seoul, Republic of Korea. 3Department of Cardiothoracic Surgery, Stanford University, Stanford, California, USA. 4Department of Physiology, McGill University, Montreal, Quebec, Canada.

Cystic fibrosis (CF) is caused by dysfunction of the CF transmembrane conductance regulator (CFTR), an anion channel whose dysfunction leads to chronic bacterial and fungal airway infections via a pathophysiological cascade that is incompletely understood. Airway glands, which produce most airway mucus, do so in response to both acetylcholine (ACh) and vasoactive intestinal peptide (VIP). CF glands fail to secrete mucus in response to VIP, but do so in response to ACh. Because vagal cholinergic pathways still elicit strong gland mucus secretion in CF subjects, it is unclear whether VIP-stimulated, CFTR-dependent gland secretion participates in innate defense. It was recently hypothesized that airway intrinsic neurons, which express abundant VIP and ACh, are normally active and stimulate low-level gland mucus secretion that is a component of innate mucosal defenses. Here we show that low levels of VIP and ACh produced significant mucus secretion in human glands via strong synergistic interactions; synergy was lost in glands of CF patients. VIP/ACh synergy also existed in pig glands, where it was CFTR dependent, mediated by both Cl− and HCO3−, and clotrimazole sensitive. Loss of “housekeeping” gland mucus secretion in CF, in combination with demonstrated defects in surface epithelia, may play a role in the vulnerability of CF airways to bacterial infections.

Introduction

The recessive genetic disease cystic fibrosis (CF) is caused by the dysfunction of CF transmembrane conductance regulator (CFTR), an anion channel that is activated by pathways that elevate cAMP. In some epithelia, such as intestine (1, 2), pancreatic ducts (3, 4), and airway submucosal glands (5), CFTR mediates Cl− or HCO3−-dependent fluid secretion, and the loss of CFTR causes reduced fluid secretion in those organs. The most serious clinical problem in CF is lung damage caused by chronic bacterial airway infections. The bacteria in CF airways reside in the mucus, which in normal airways is sterile and mobile (6), suggesting that CF mucus is abnormal both in its ability to be cleared from the airways (7) and in its antimicrobial properties (8). Most airway mucus is thought to arise from submucosal glands (9, 10), and in the only direct comparisons ever made of airways with and without glands, airways with glands secreted much more lysozyme and were more resistant to bacterial infections, even though no central innervation of the glands was present (11, 12). We hypothesize that abnormalities in airway gland mucus, secondary to loss of CFTR-mediated anion secretion, is a significant contributor to airways pathology in CF (13).

In humans and pigs, airway submucosal glands secrete mucus in response to both acetylcholine (ACh) and vasoactive intestinal peptide (VIP) (5, 14). CF glands no longer secrete mucus in response to VIP (5), but do respond to carbachol (15). The nonhydrolyzable ACh analog carbachol produces maximal mucus secretion rates (to 10 μM) that are about 2- to 3-fold greater than those caused by maximal VIP, and most studies of glands use maximal levels of cholinergic stimulation (10, 14). However, such stimuli are probably rarely experienced except in acute crises. Instead, mundane pathogens and irritants encountered continuously during normal breathing are more likely to produce low levels of stimulation via both neural and non-neural pathways. The complex innervation of airway glands includes neurons intrinsic to the airways and employs multiple neurotransmitters, sometimes localized in the same neurons (16–21). These facts, in addition to the ability of centrally denervated airways in lung transplant patients to resist chronic infections and the presence of CFTR-dependent local pathways in mouse airways (22), have led to a renewed interest in the local neural control of airway glands (23) and argue that the consequences of low-level stimulation by mixed agonists, which probably more closely approximate physiological conditions, need to be evaluated, particularly with reference to gland function in CF (see Discussion).

To our knowledge, the consequences of combinations of low-level agonists on secretion of airway gland mucus have not previously been studied. The concentration of agonists that glands experience during normal breathing is not known, but airway vagal efferents display tonic activity during breathing (24), suggesting a resting level of neural excitation of glands. Therefore, in order to determine whether any interactions exist among low levels of agonists, here we used optical methods to measure mucus secretion rates from single glands in situ (25) in response to VIP and carbachol, especially at nanomolar concentrations that might be expected to mimic routine physiological input to the glands. We demonstrated strong synergistic interactions between cholinergic and noncholinergic pathways in humans; importantly,

Nonstandard abbreviations used: ACh, acetylcholine; CF, cystic fibrosis; CFTR, CF transmembrane conductance regulator; 1-EBIO, 1-ethyl-benzimidazolinone; NKCC, Na+, K+, 2 Cl cotransporter; VIP, vasoactive intestinal peptide.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 117:3118–3127 (2007). doi:10.1172/JCI31992.
we found that those interactions were lost in human CF glands. We also demonstrated and analyzed VIP-carbachol synergy in pig submucosal glands. Some of these results have been reported in preliminary form in abstracts (26–28).

**Results**

**Dose-response relations for single gland mucus secretion in human and pig airway glands.** To begin the analysis of interactions between low levels of agonists, we first established dose-response relations for carbachol and VIP in non-CF human bronchi and tracheae and in pig tracheae, using optical methods to determine the rate of mucus secretion from single glands. As shown in Figure 1, pigs and humans had very similar dose-response relations for both agonists. For pigs the threshold (defined as the concentration which produced an obvious increase in mucus secretion rates for at least 2 glands in the optical field) for carbachol stimulation of gland mucus secretion was approximately 100 nM, the EC50 was 590 ± 16 nM, and the approximate Vmax achieved with 10 μM carbachol was 3.43 ± 0.29 nl/min/gland (n = 4, 27–43 glands; Figure 1A). For humans, the threshold for carbachol stimulation of gland secretion was approximately 50 nM, the EC50 was 545 ± 42 nM, and the approximate Vmax achieved with 10 μM VIP was 1.58 ± 0.18 nl/min/gland (n = 4, 21 glands; Figure 1B). The threshold for VIP in pigs was approximately 20 nM, the EC50 was 834 ± 311 nM, and the extrapolated Vmax (not achieved with the maximal concentration of 10 μM VIP) was 1.54 ± 0.09 nl/min/gland (n = 4, 24 glands; Figure 1C). The threshold for VIP in humans was approximately 50 nM, the EC50 was 717 ± 76 nM, and maximal stimulation (probably less than Vmax and achieved with 10 μM VIP) was 3.55 ± 0.11 nl/min/gland (n = 4, 25–36 glands; Figure 1D).

**Human glands show synergistic secretory responses to VIP and carbachol.** We used the dose-response relations to select concentrations for testing synergistic effects among VIP and carbachol. For human airway glands, subthreshold concentrations of VIP (10 nM) and carbachol (10 nM) produced significant mucus secretion when combined (Figure 2). Images of mucus bubbles under oil just before and 30 minutes after the combined stimulation are shown in Figure 2A. A plot of mucus volume versus time for 10 individual glands from a single subject is shown in Figure 2B, and summary data for 138 airway glands from 16 human subjects are shown in Figure 3. Essentially identical results were obtained for tracheal glands obtained from 9 donor tissues and from bronchial glands obtained from 7 controls with disease other than CF. Human glands secreted mucus in response to the combined stimuli at an average rate of 0.30 ± 0.18 nl/min/gland. This was a significant increase (P < 0.001) over secretion in response to either agent alone and was approximately 20% of Vmax to VIP and 10% of Vmax to 10 μM carbachol. In terms of concentrations, the mucus secretion produced by 10 nM VIP combined with 10 nM carbachol was approximately what would be expected with either 100 nM carbachol or 400 nM VIP alone. In 2 experiments with a single human subject with chronic obstructive pulmonary disease (disease control), 8 glands were followed for longer periods to determine whether there were delayed responses to 10 nM VIP or carbachol alone, and 13 glands were followed for 40–50 minutes with VIP and 1 hour with carbachol before applying the combined stimuli. No increase in mucus secretion was observed during these more prolonged periods, but rapid increases in secretion occurred to the combined stimuli for 10 of 13 glands (data not shown).

**CF glands lack a synergistic secretory response to VIP and carbachol.** Previous work showed that glands from subjects with CF are refractory to stimulation with VIP or forskolin, although they still respond to carbachol (5). To determine whether synergy between VIP and carbachol was also affected in subjects with CF, we applied...
the same paradigm that produced synergy in human control tissues to CF tissues. In marked contrast with controls, we found that CF glands failed to respond to the combination of carbachol and VIP that was efficacious in controls (Figure 2C and Figure 3). The mean response was essentially 0 (0.002 ± 0.008 nl/min; n = 7, 71 glands) and did not differ significantly from the response to either agent alone. However, the CF glands were viable because they still responded vigorously to 1 μM carbachol, which produced mucus secretion of 3.10 ± 1.13 nl/min/gland (Figure 3, inset).

Synergistic stimulation of mucus secretion by VIP and carbachol in pig airway glands. Because pig airway tissues are consistently available, we sought to determine whether pig glands displayed a similar form of synergy so that we could use pigs to begin analyzing the mechanisms of synergy. We found that pig tracheal glands, like human glands, showed marked synergy between subthreshold concentrations of VIP and carbachol (Figure 4). A single experiment recording 7 responding glands is shown in Figure 4A, and the mean mucus secretion rate for each condition (n = 4, 34 glands) is shown in Figure 4B. The response in the combined condition was significantly increased versus either condition alone, producing a mean mucus secretion rate of 0.33 ± 0.11 nl/min/gland (P < 0.01). Atropine (1 μM) had no effect on mucus secretion produced by suprathreshold levels of VIP used alone (data not shown), but, as expected, it abolished synergy between low levels of carbachol and VIP (n = 3, 19 glands; P < 0.05).

We next determined the interactions of VIP and carbachol over a range of agonist concentrations (n = 5, 9–36 glands, per condition). We first tested a 1,000-fold range of VIP concentrations (1 nM to 10 μM) either alone or with the addition of 20 or 50 nM carbachol, which are subthreshold when used alone in pigs. As shown in Figure 5A, either concentration of carbachol markedly increased mucus secretion for all VIP concentrations of 10 nM or greater. We then held the VIP concentration constant at 10 nM and added increasing concentrations of carbachol (1 nM to 10 μM). As shown in Figure 5B, synergy (and indeed additivity) was lost at carbachol concentrations greater than 100 nM, after which there was complete occlusion (n = 4, 7–45 glands, per condition). The dose response to carbachol alone was well fitted with a single sigmoid (P < 0.001), but the combination of VIP and carbachol was best fit with 2 sigmoids (the double sigmoid was better than a single sigmoid; P < 0.025), suggesting a second process was operating at lower concentrations.

Synergy dependent on cAMP and CFTR. To begin the analysis of the mechanisms responsible for synergy between carbachol and VIP, we first asked whether forskolin, which bypasses VIP receptors and directly activates adenylate cyclase, can substitute for VIP in the synergy paradigm. When combined with 20 nM carbachol, 100 nM forskolin (a subthreshold concentration for pig and human gland mucus secretion when used alone; data not shown), produced in pigs a mucus secretion rate of 0.26 ± 0.08 nl/min/gland (Figure 4C), similar to the synergy produced by VIP (Figure 4B). Forskolin was also tested in experiments with 2 humans using 100 nM forskolin alone or in combination with 10 nM carbachol. Of 10 glands tested, none responded to either agent alone, but 8 of 10 glands secreted mucus in response to the combination of forskolin and carbachol.
Thus, forskolin could substitute for VIP to produce synergy with carbachol. This is of interest because a previous report of VIP-ACh synergy for glyconjugate release by cat glands found that db-cAMP could not substitute for VIP (29). This point is addressed again in Discussion.

Fluid secretion by pig airway glands is driven by anion secretion (10, 30–34), and the lack of synergy in tissues from humans with CF indicated that synergy in humans requires CFTR. We next sought to determine the relative contributions of CFTR and Ca\(^{2+}\)-activated chloride channels to the synergistic effect in pig glands. For this purpose, we stimulated mucus secretion with 20 nM carbachol plus 10 nM VIP, which gave a mucus secretion rate of 0.29 ± 0.09 nl/min/gland, and then added either 40 μM niflumic acid to inhibit Ca\(^{2+}\)-activated chloride channels (35) or 20 μM CFTRinh-172 to inhibit CFTR channels (36) (Figure 6A). The synergistic response was not inhibited by 40 μM niflumic acid (mucus secretion rate, 0.27 ± 0.12 nl/min/gland; NS). In contrast, 20 μM CFTRinh-172 reduced the response significantly (mucus secretion rate, 0.08 ± 0.01 nl/min/gland; \(P < 0.01\)). Inhibition with CFTRinh-172 was consistent with the lack of synergy in humans who lacked functional CFTR, as shown in Figure 2C and Figure 3. The lack of inhibition by niflumic acid could mean that Ca\(^{2+}\)-activated chloride channels are not activated by low levels of carbachol, but before making this conclusion, we needed a positive control for the effects of niflumic acid on gland mucus secretion.

Role of Ca\(^{2+}\)-activated Cl\(^{-}\) channels. Mucus secretion by glands becomes at least partially independent of CFTR at higher concentrations of carbachol (refs. 5, 15, 22, 26, 37–40, and Figure 3, Figure 3

Summary data comparing synergistic stimulation of mucus secretion in human control glands with the lack of synergy in CF glands. Data was obtained from 9 donor tracheae (72 glands), bronchi from 7 disease controls (66 glands), and bronchi from 7 patients with CF (71 glands). For each control group, the combined treatments produced significantly greater mucus secretion than did either treatment alone, but CF subjects did not respond to the combined treatment, and the difference between CF and either control group was significant. **\(P < 0.01\); ***\(P < 0.001\). Inset: CF glands were still viable, as determined by their robust secretion in response to a 100-fold higher concentration of carbachol.

Figure 3

Figure 4

Pig airway glands also show synergy between VIP and carbachol stimulation of mucus secretion. (A) An example of 7 tracheal glands from a single pig trachea stimulated with 20 nM carbachol, 10 nM VIP, and the combination. As in humans, synergy was observed with the combined treatment; a slightly higher carbachol concentration was used with pigs. (B) Summary data for 34 glands from 4 pigs. The response to combined agonists was significantly greater than either agonist used alone. The synergistic response was blocked by atropine (19 glands in 3 pigs). (C) Summary data for forskolin (Fors) and carbachol stimulation of mucus secretion for 18 glands from 3 pigs demonstrated that forskolin can substitute for VIP to produce synergy with carbachol. Note that 100 nM forskolin was required to see synergy equivalent to 10 nM VIP. *\(P < 0.05\); **\(P < 0.01\).
inset), presumably because another apical Cl– channel is activated. Therefore, we stimulated tissues with a 5-fold greater concentration of carbachol (100 nM) in the absence of VIP — this level of carbachol produced a rate of mucus secretion similar to that produced by 20 nM carbachol plus 10 nM VIP (0.22 ± 0.02 nl/min/gland) — and tested again with the same inhibitors (Figure 6B). Glands that secreted mucus in response to 100 nM carbachol alone here showed a different pattern of inhibition: niflumic acid and CFTRinh-172 each significantly inhibited the response by similar amounts. Inhibition by niflumic acid is consistent with activation of another anion channel, but inhibition by CFTRinh-172 was unexpected. This indicates that CFTR is partially active in these conditions, either because it has some level of basal activity or because it is being activated by this higher level of carbachol. The results to this point indicated that activation of CFTR is required for synergy and suggested that Ca2+-activated chloride channels are minimally involved, because niflumic acid had no detectable effect; the residual mucus secretion in the presence of CFTRinh-172 may be explained by the incomplete inhibition of CFTR seen with this compound in some conditions (41, 42).

**Role of Ca2+-activated K+ channels in synergy.** Anion-driven fluid secretion by many epithelia is augmented by cell hyperpolarization, secondary to the activation of Ca2+-activated K+ channels (43). Thus, we considered the possibility that at the low levels of agonists used here, VIP activates only (or primarily) CFTR, and carbachol activates only (or primarily) Ca2+-activated K+ channels. To inhibit Ca2+-activated K+ channels, we applied clotrimazole (44) while stimulating glands with a just-suprathreshold concentration of VIP (100 nM) and a subthreshold concentration of carbachol (50 nM). These concentrations produced marked synergy (see Figure 5), but also provided a level of mucus secretion mediated by VIP alone against which the effects of clotrimazole could be tested. In different experiments, clotrimazole (25 μM) was applied either before or after the combination of VIP and carbachol. Clotrimazole abolished synergy whether added after (Figure 7A) or before (Figure 7B).
Synergistic stimulation of mucus secretion from pig airway glands depends upon the recruitment of Ca\(^{2+}\)-activated K\(^{+}\) channels. (A) The response to 100 nM VIP plus 50 nM carbachol was substantially reduced by 25 \(\mu\)M clotrimazole. (B) Clotrimazole did not inhibit the response to VIP alone, but prevented the increase observed with carbachol combined with VIP. (C) 1-EBIO alone (500 \(\mu\)M) did not stimulate mucus secretion, but significantly enhanced secretion produced by 100 nM VIP. In A–C, each point represents the mucus secretion rate of a single gland averaged over the preceding 20-minute period of stimulation. Conditions were separated by 1-minute washes. The connecting lines are visual aids to allow tracking of each gland in the various conditions. (D) Summary data for experiments with clotrimazole (Clot; left, \(n = 3, 23\) glands) and 1-EBIO (right, \(n = 3, 26\) glands). *\(P < 0.05\).

Discussion

The purpose of these experiments was to test the hypothesis that airway glands secrete significant amounts of mucus in response to low levels of VIP and ACh applied together. We asked this question because ACh and VIP are abundant neurotransmitters used by airway neurons (reviewed in ref. 23) and because of a new hypothesis that routine, “housekeeping” mucus secretion by airway glands is blocked the other can partially compensate (30–32, 47). In single gland studies using maximal stimulation (10 \(\mu\)M carbachol or 10 \(\mu\)M forskolin), mucus secretion was inhibited 50%–60% either by bumetanide, which inhibits the Na\(^{+}\)-K\(^{+}\)-2 Cl\(^{−}\) cotransporter (NKCC), or by HCO\(_3\)\(^−\) replacement with HEPES, which was used to abrogate HCO\(_3\)\(^−\)-mediated fluid secretion. The combination of bumetanide and HCO\(_3\)\(^−\) replacement reduced mucus secretion by at least 90% (14). To determine whether these transporters play the same roles in synergistic secretion, we stimulated pig tracheal glands with 100 nM VIP combined with 50 nM carbachol either in Krebs-Ringer buffer or in the presence of bumetanide, HEPES, or the combination (\(n = 2–3, 11–22\) glands). As shown in Figure 8, interference with transport of either anion inhibited mucus secretion in response to VIP or VIP plus carbachol by 45%–75%, and the combination of bumetanide and HEPES inhibited mucus secretion by approximately 90%. A potentially interesting point is that bumetanide inhibited the synergistic response more effectively (78%) than did HEPES replacement of HCO\(_3\)\(^−\) (\(P < 0.02\)). This contrasts with inhibition of responses to saturating levels of VIP, forskolin, or carbachol used individually, which are equally inhibited by HEPES or bumetanide (14, 25).

Mucus secretion relies on both Cl\(^−\) and HCO\(_3\)\(^−\) transport. Prior work has shown that pig gland mucus secretion depends on both Cl\(^−\) and HCO\(_3\)\(^−\) transport, and when one ion transport pathway is blocked the other can partially compensate (30–32, 47). In single gland studies using maximal stimulation (10 \(\mu\)M carbachol or 10 \(\mu\)M forskolin), mucus secretion was inhibited 50%–60% either by bumetanide, which inhibits the Na\(^{+}\)-K\(^{+}\)-2 Cl\(^−\) cotransporter (NKCC), or by HCO\(_3\)\(^−\) replacement with HEPES, which was used to abrogate HCO\(_3\)\(^−\)-mediated fluid secretion. The combination of bumetanide and HCO\(_3\)\(^−\) replacement reduced mucus secretion by at least 90% (14). To determine whether these transporters play the same roles in synergistic secretion, we stimulated pig tracheal glands with 100 nM VIP combined with 50 nM carbachol either in Krebs-Ringer buffer or in the presence of bumetanide, HEPES, or the combination (\(n = 2–3, 11–22\) glands). As shown in Figure 8, interference with transport of either anion inhibited mucus secretion in response to VIP or VIP plus carbachol by 45%–75%, and the combination of bumetanide and HEPES inhibited mucus secretion by approximately 90%. A potentially interesting point is that bumetanide inhibited the synergistic response more effectively (78%) than did HEPES replacement of HCO\(_3\)\(^−\) (\(P < 0.02\)). This contrasts with inhibition of responses to saturating levels of VIP, forskolin, or carbachol used individually, which are equally inhibited by HEPES or bumetanide (14, 25).

Figure 7

Synergistic stimulation of mucus secretion from pig airway glands depends upon the recruitment of Ca\(^{2+}\)-activated K\(^{+}\) channels. (A) The response to 100 nM VIP plus 50 nM carbachol was substantially reduced by 25 \(\mu\)M clotrimazole. (B) Clotrimazole did not inhibit the response to VIP alone, but prevented the increase observed with carbachol combined with VIP. (C) 1-EBIO alone (500 \(\mu\)M) did not stimulate mucus secretion, but significantly enhanced secretion produced by 100 nM VIP. In A–C, each point represents the mucus secretion rate of a single gland averaged over the preceding 20-minute period of stimulation. Conditions were separated by 1-minute washes. The connecting lines are visual aids to allow tracking of each gland in the various conditions. (D) Summary data for experiments with clotrimazole (Clot; left, \(n = 3, 23\) glands) and 1-EBIO (right, \(n = 3, 26\) glands). *\(P < 0.05\).
and K⁺ secretion and was augmented by cellular hyperpolarization. A minimal model of fluid secretion by gland serous cells is shown in Figure 9. This model has much in common with a model developed for sweat secretion (48, 49). Our data are consistent with the following points. (a) Low concentrations of ACh activate K⁺ channels but do not activate any apical anion conductances (Figure 9A). (b) Low concentrations of VIP can activate CFTR but apparently have little effect on basolateral K⁺ channels (Figure 9B). Therefore, little or no fluid secretion occurs for these 2 conditions. (c) When combined, the dual activation of basolateral K⁺ channel and apical CFTR supports anion-mediated fluid secretion (Figure 9C). NKCC and other basolateral transporters are active in this condition, but the exact mechanisms for that activation are unclear. (d) Higher levels of ACh alone recruit Ca²⁺-activated chloride channels and so produce fluid secretion (Figure 9D). Higher concentrations of VIP alone can recruit basolateral cAMP-dependent K⁺ channels and also support fluid secretion (5). Thus, at higher concentrations of these agonists, or higher rates of neural activity, each agonist alone can support mucus secretion. In this model, gland mucus secretion in response to VIP alone or to VIP in combination with low levels of carbachol depends absolutely on CFTR, whereas mucus secretion in response to higher levels of carbachol is, at least in part, independent of CFTR. Too many uncertainties remain to allow a quantitative model of gland secretion to be formulated and tested.

**Figure 8**

Contribution of Cl⁻ transport (NKCC1) and HCO₃⁻ transport to mucus secretion produced by 100 nM VIP or 100 nM VIP plus 50 nM carbachol. The mucus secretion rate prior to stimulation in these experiments was essentially 0 (<0.02 nl/min/gland). VIP-stimulated mucus secretion was equally and significantly (P < 0.05) inhibited by the NKCC inhibitor bumetanide or by replacement of HCO₃⁻ with HEPEs, and the combined treatment eliminated greater than 90% of mucus secretion. The combined agonists bumetanide and HEPEs again caused significant inhibition of mucus secretion that was additive, but in this condition bumetanide was significantly more inhibitory than was HEPEs (P < 0.02). For each condition the number of subjects and number of glands (in parentheses) is shown.

**Figure 9**

A minimal gland cell model for synergistic interactions between nanomolar carbachol and VIP on submucosal gland fluid secretion. (A) Low levels of ACh do not produce effective fluid secretion because they activate K⁺ channels (K₁) but not apical Cl⁻ channels. (B) Low levels of VIP do not produce effective fluid secretion because they activate CFTR but not K⁺ channels. (C) When combined at low levels, ACh (i) activates Ca²⁺-activated K⁺ channels (K₂) to increase the driving force through CFTR; it may also increase activity of basolateral transporters. VIP opens CFTR (ii), allowing electrogenic, anion-mediated fluid secretion. (D) At higher levels of ACh, apical Ca²⁺-activated chloride channels (CaCC) are activated (iii); at higher levels of VIP, cAMP-activated K⁺ channels (K₃) are activated (iv). Thus, at higher rates of stimulation each pathway alone can produce enough fluid to support mucus secretion. Major unresolved points are the types of gland mucus secretory cells that express Ca²⁺-activated chloride channels (serous, mucous, or both) and the relative magnitudes of the apical conductances mediated by each type of channel. The apical K⁺ channel is based on single channel recordings in Calu-3 cells (61) and gland cells (J.V. Wu, unpublished observations).
Both humans and pigs. Notably, we have also demonstrated synergy in WT but not cfr+/− mouse tracheal submucosal glands (our unpublished observations).

**Functional relevance of low levels of gland mucus secretion.** With 50 nM carbachol plus 50 nM VIP, mucus secretion was about 1 nl/min/gland (Figure 5). In the trachea, glands are present at a density of approximately 1 per mm² (52). If the glands were the only source of fluid, and in the absence of other factors, the observed mucus secretion rate would produce a 7-μm-deep film of surface fluid within about 7 minutes, which is sufficient for mucociliary clearance (53). Much of the fluid secreted into the airways is reabsorbed, raising interesting questions about the fate of macromolecular components of mucus.

Little information is available on levels of neural input to glands, and most studies emphasize vagal control via centrally mediated lung defense reflexes. However, evidence is emerging that networks of airway intrinsic neurons can mediate mucus secretion in the absence of central input (23). For example, transplanted lungs lack central neural input and must rely on the intrinsic nervous system for basal mucus secretion and to respond to mucosal insults (22); mucus clearance continues in transplanted lungs at either a similar (54) or a reduced rate (55, 56), and glands in tracheae explanted into nude mice still secrete lysozyme in the absence of any central neural connections; they produce 8.5-fold more lysozyme than is found in airways without glands (12). Intact central connections provide an additional level of central excitatory vagal tone (24), and no neural inhibition of airway intrinsic neurons is thought to exist (24). The synergy observed between ACh and VIP, both abundantly expressed in airway intrinsic neurons, may be important for basal gland mucus secretion and local responses to mucosal irritants (22), but experiments with intact lungs are required to address these questions.

**Relation to CF.** Gland mucus secretion is absolutely CFTR dependent when it is mediated by VIP or forskolin alone (5). In the present study, we have shown that it is also CFTR dependent when evoked synergistically by VIP and ACh. It may be relevant that mice lacking VIP have increased airway inflammation (57). It is also interesting that 2 previous studies reported reduced levels of VIP nerves around CF sweat glands (58) and VIP binding sites also interest us that 2 previous studies reported reduced levels of VIP nerves around CF sweat glands (58) and VIP binding sites

---

**Table 1**

<table>
<thead>
<tr>
<th>Subject characteristics</th>
<th>Donor (n)</th>
<th>Other disease (n)</th>
<th>CF (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean ± SD)</td>
<td>38 ± 13</td>
<td>57 ± 9</td>
<td>27 ± 16</td>
</tr>
</tbody>
</table>

*Age and sex characteristics were not retrieved for 1 donor trachea.*

---

**Methods**

**Human airway preparations.** Human tracheal and bronchial tissues were obtained following lung transplants and were used within 24 hours. These studies were approved by the Institutional Review Boards of Stanford University, and tissue was only used from patients who had provided written informed consent. Data were obtained from 9 donor tracheae, 7 bronchi from patients with CF, and 7 bronchi from patients who were transplanted for diseases other than CF. Three lungs were from patients who had chronic obstructive pulmonary disease, and the remaining 4 non-CF tissues were from patients with α1-antitrypsin deficiency, interstitial pneumonitis type II autoimmune hepatitis, transposition of greater vessels, and idiopathic pulmonary fibrosis-usual interstitial pneumonia. Results for these 7 subjects did not differ from one another or from the donor trachea, so results from all 16 control subjects were combined for comparison with CF subjects. Subject characteristics are given in Table 1.

**Porcine preparations.** Pig tracheae were obtained from fresh carcasses of juvenile Yorkshire pigs of either sex weighing 35–50 kg following acute experiments carried out for other purposes. No pigs were sacrificed specifically for the present experiments, nevertheless, the experiments were approved by Stanford University’s Institutional Animal Care and Use Committee (IACUC). A total of 34 pig tracheae were used for these experiments.

Human and pig tissues were treated the same after harvesting. They were transported to the laboratory in cold Physiolsol solution (Abbott Laboratories) and were then transferred to ice-cold Krebs-Ringer bicarbonate buffer bubbled with 95% O₂ and 5% CO₂, where they were maintained until use. The Krebs-Ringer buffer composition was 115 mM NaCl, 2.4 mM K₂HPO₄, 0.4 mM KH₂PO₄, 25 mM NaHCO₃, 1.2 mM MgCl₂, 1.2 mM CaCl₂, 10 mM glucose, and 1.0 mM indomethacin. The pH was 7.4 and osmolality was adjusted to approximately 290 milliosmoles.

A piece of ventral trachea or bronchus of about 0.5 cm² was pinned mucosal side up, and the mucosa with underlying glands was dissected from the cartilage and mounted in a 35-mm-diameter plastic Petri dish lined with Sylgard (Dow Corning Corp.), with the serosa in the bath (~1 ml volume) and the mucosa in air. The tissue surface was cleaned and blotted dry with cotton swabs and further dried with a stream of gas, after which 20–30 μl of water-saturated mineral oil was placed on the surface. The tissue was warmed to 37°C at a rate of about 1.5°C/min and continuously superfused with warmed, humidified 95% O₂ and 5% CO₂. Pharmacological agents were diluted to final concentrations with warmed, gassed bath solution and were added to the serosal side by complete bath replacement.

**Optical measurements.** Bubbles of mucus within the oil layer were visualized by oblique illumination and digital images were captured with the macro lens of a Nikon digital camera. Each image contained an internal reference grid to compensate for any minor adjustments in magnification made during the experiment. Stored images were analyzed either by direct measurement or with NIH ImageJ software (http://rsb.info.nih.gov/ij/). Mucus volumes were determined from the size of the spherical bubbles; bubbles that were not approximately spherical were omitted from mucus secretion rate analyses. Details of these methods are given in ref. 25.
Acknowledgments

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases grant RO1-S1817 (J.J. Wine), the Cystic Fibrosis Foundation, and Cystic Fibrosis Research Inc. We thank Hyun Seung Choi of Yonsei University College of Medicine for help with some of the experiments, and Jonathan Philips of the Schering-Plough Research Institute for guiding us to early literature on lung denervation. Tony Nguyen provided technical support, and we are grateful to Jennifer Lyons for discussions. Finally, we are indebted to the Stanford lung transplant team and especially the patients and the families of donors, whose cooperation made this research possible.

Received for publication March 1, 2007, and accepted in revised form June 20, 2007.

Address correspondence to: Jeffrey J. Wine, Cystic Fibrosis Research Laboratory, Room 450, Building 420, Main Quad, Stanford University, Stanford, California 94305-2130, USA. Phone: (650) 725-2462; Fax: (650) 725-5699; E-mail: wine@stanford.edu.